Company Description
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration.
The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus.
The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 15, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Robb Knie |
Contact Details
Address: 1177 Avenue of the Americas, Suite 5066 New York, New York 10036 United States | |
| Phone | (646) 756-2997 |
| Website | hoththerapeutics.com |
Stock Details
| Ticker Symbol | HOTH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.60 |
| CIK Code | 0001711786 |
| CUSIP Number | 44148G105 |
| ISIN Number | US44148G2049 |
| Employer ID | 82-1553794 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robb Knie | Founder, President, Chief Executive Officer and Chairman |
| David S. Briones | Chief Financial Officer |
| Hayley Springer | Executive Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 16, 2025 | ARS | Filing |
| Jun 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 16, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 9, 2025 | 8-K | Current Report |
| May 16, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 2, 2025 | 8-K | Current Report |
| Apr 15, 2025 | 8-K | Current Report |